ViiV Healthcare: Lotivibart Shows 94% Viral Suppression in Long-Acting HIV Treatment
- 94% of adults on stable therapy maintained viral suppression with lotivibart dosed every four months.
- The study will evaluate a twice-yearly intravenous dosing interval for lotivibart.
- Lotivibart was generally well tolerated, with fewer adverse events in the IV group.
- Higher grade infusion-site reactions were reported in 16% of the SC group, none in the IV group.
Study Overview
ViiV Healthcare reported positive 12-month data from the phase IIb EMBRACE study, showing that lotivibart, a broadly neutralising antibody, maintained viral suppression in 94% of adults on stable HIV therapy. The regimen involved intravenous lotivibart every four months combined with monthly intramuscular cabotegravir (CAB LA).
Progression and Tolerability
The study will now evaluate a twice-yearly intravenous dosing interval for lotivibart. Lotivibart was generally well tolerated, with fewer adverse events reported in the intravenous group compared to the subcutaneous group.
Adverse Events
Adverse events related to lotivibart were less common in the intravenous group (24%) compared to the subcutaneous group (53%). Higher grade infusion-site reactions were reported in 16% of participants in the subcutaneous group, while none were reported in the intravenous group.
Previous Findings
These findings build on six-month data presented earlier, which first demonstrated that lotivibart, administered every four months with CAB LA, effectively maintained an undetectable viral load in adults on stable HIV therapy.
Source: GSK